Novartis exec makes Ipsen switch

20 January 2017

Harout Semerjian has been named Ipsen’s (Euronext: IPN) new head of specialty care, international region and global franchises.

He joins the French drugmaker from Swiss pharma giant Novartis (NOVN: VX), becoming a member of Ipsen’s executive leadership team.

Mr Semerjian has spent more than 23 years working in pharma, including the last 17 with Novartis, focused on oncology and specialty care. He took on leadership roles with increasing responsibility across the USA, Canada, Europe, Middle East and North Africa in addition to headquarter-based roles.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK